Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process

Journal of Virological Methods

Volumn 176, Issue 1-2, 2011, Pages 60-68

  Liu, Chia Chyi ^a   Chang, Hsuen Wen ^a   Yang, Grace ^a   Chiang, Jen Ron ^b   Chow, Yen Hung ^a   Sai, I Hsi ^a   Chang, Jui Yuan ^a   Lin, Sue Chen ^a   Sia, Charles ^a   Hsiao, Chia Hsin ^a   Chou, Ai Hsiang ^a   Chong, Pele ^a,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b Vaccine Center   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ELISA; Enterovirus 71; Neutralization epitope; Process analytical technology; Viral antigen

Indexed keywords

ANTISERUM; ENTEROVIRUS 71 VACCINE; INACTIVATED VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN VP2; RABBIT ANTISERUM; UNCLASSIFIED DRUG; VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG MANUFACTURE; DRUG POTENCY; ENTEROVIRUS 71; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL FILTRATION CHROMATOGRAPHY; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS MONITORING; PROCESS TECHNOLOGY; PROTEIN CONTENT; PROTEIN PURIFICATION; PROTEIN STABILITY; QUANTITATIVE ASSAY; ROLLER BOTTLE TECHNOLOGY; SENSITIVITY AND SPECIFICITY; STORAGE TEMPERATURE; SUPERNATANT; VIRUS CULTURE; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BIOTECHNOLOGY; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; RABBITS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; VACCINATION; VERO CELLS; VIRAL VACCINES;

GALLUS GALLUS; HUMAN ENTEROVIRUS 71; MUS; ORYCTOLAGUS CUNICULUS;

EID: 79960609635     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.06.001     Document Type: Article

References (20)

1. AbuBakar S., Chee H.Y., Al-Kobaisi M.F., Xiaoshan J., Chua K.B., Lam S.K. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res. 1999, 61:1-9.
2. Alexander J.P., Baden L., Pallansch M.A., Anderson L.J. Enterovirus 71 infections and neurologic disease (United States), 1977-1991. J. Infect. Dis. 1994, 169:905-908.
3. Chang L.Y., Huang Y.C., Lin T.Y. Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 1988, 352:367-368.
4. Chang H.W., Liu C.C., Lin M.H., et al. Isolation and characterization of murine monoclonal antibodies generated against a clinical isolate of enterovirus 71. J. Virol. Methods 2011, 173:189-195.
5. Chen H.L., Huang J.Y., Chu T.W., Tsai T.C., Hung C.M., Lin C.C., et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008, 26:2882-2889.
6. Chumakov M., Voroshilova M., Shindarov L., Lavrova I., Gracheva L., Koroleva G., et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch. Virol. 1979, 60:329-340.
7. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26:1855-1862.
8. Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007, 125:61-68.
9. Gilbert G.L., Dickson K.E., Waters M.J., Kennett M.L., Land S.A., Sneddon M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr. Infect. Dis. J. 1988, 7:484-488.
10. Hames B.D. Gel Electrophoresis of Proteins: A Practical Approach 1988, Oxford University Press, New York. third ed.
11. Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N. Engl. J. Med. 1999, 341:929-935.
12. Lee M.S., Chang L.Y. Development of enterovirus 71 vaccines. Expert Rev. Vaccines 2010, 9:149-156.
13. Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liu S.J., et al. Identification of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011, doi:10.1016/j.vaccine.2011.04.010.
14. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 2002, 26:91-107.
15. McMinn P.C. Enterovirus 71 in the Asia-Pacific region: an emerging cause of acute neurological disease in young children. Neurol. J. Southeast Asia 2003, 8:57-63.
16. Qiu J. Enterovirus 71 infection: a new threat to global public health?. Lancet Neurol. 2008, 7:868-869.
17. Reed L.J., Muench H. A simple method of estimating 50 percent end-points. Am. J. Hyg. 1938, 27:493-497.
18. Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 1974, 129:304-309.
19. Tung W.S., Bakar S.A., Sekawi Z., Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet. Vaccines Ther. 2007, 5:6.
20. Xu J., Qian Y., Wang S., Serrano J.M.G., Li W., Huang Z., Lu S. EV71: an emerging infectious disease vaccine target in the Far East?. Vaccine 2010, doi:10.1016/j.vaccine.2010.03.003.